in-PharmaTechnologist RSS

OptiNose OKed for Phase III trial of nasal delivery tech

Gareth.MACDONALD@wrbm.com (Gareth MACDONALD) — Thu, 09 Feb 2012 13:05:59 +0100

OptiNose has received US FDA approval to start Phase III trials of its nasal delivery device.

China healthcare spending up despite economic fears, BD says

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Thu, 09 Feb 2012 12:24:08 +0100

BD posted double-digit revenue growth in China as government spending on healthcare continued despite economic pressures.

Lilly teams with Bend over spray-dried dispersion tech

Natalie.MORRISON@wrbm.com (Natalie MORRISON) — Thu, 09 Feb 2012 11:25:30 +0100

Eli Lilly has licensed a spray-dried dispersion (SDD) technology from Bend Research, expanding its manufacturing capabilities.

AMPAC sales jump 50% on return of antiviral revenues

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Thu, 09 Feb 2012 11:36:13 +0100

AMPAC Fine Chemicals posted a 50 per cent jump in revenues after the return of sales from its antiviral business.

AMRI posts Q4 loss but expects contracting revs to grow in 2012

Gareth.MACDONALD@wrbm.com (Gareth MACDONALD) — Wed, 08 Feb 2012 12:42:20 +0100

AMRI posted a Q4 loss on lower sales but predicts that contracting revenues and margins will increase in 2012 thanks to cost cutting measures and new contracts

Rx-360 warns Pharmas of potential L-Arginine shortage

Gareth.MACDONALD@wrbm.com (Gareth MACDONALD) — Wed, 08 Feb 2012 10:52:16 +0100

Pharma supply chain consortium Rx-360 has advised drugmakers to check their L-Arginine stocks, warning that a recent surge in demand could limit supplies.

Cambrex on takeover hunt amid pharma fine chem consolidation

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Wed, 08 Feb 2012 11:34:18 +0100

Cambrex expects fine chemical consolidation to continue this year and is being “proactive” in its hunt for takeover targets.

GSK aims to cut time to clinic with excipient-free compression

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Wed, 08 Feb 2012 10:41:05 +0100

GSK is developing tablets it can compress without excipients to cut the time taken to reach the clinic by up to nine months.

Shanghai Pharmaceuticals buys major stake in special API maker

Natalie.MORRISON@wrbm.com (Natalie MORRISON) — Tue, 07 Feb 2012 12:54:55 +0100

Shanghai Pharmaceuticals has bought a 70 per cent stake in ingredients developer and manufacturer Changzhou Kony Pharm in a bid to boost its standing in the API market.

BAC BV and Life Teschnologies team up on processing columns

Gareth.MACDONALD@wrbm.com (Gareth MACDONALD) — Tue, 07 Feb 2012 12:53:56 +0100

BAC BV and Life Technologies have launched a new range of affinity columns will ‘unlock’ high speed affinity HPLC for pharmaceutical processing.

US consent decree act aims to stop “regulatory frenzy”

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Tue, 07 Feb 2012 12:33:50 +0100

A proposed US act aims to impose limitations on consent decrees and stop the “regulatory frenzy in Washington”.

Australia mulls chemical supply chain actions to stop terrorism

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Tue, 07 Feb 2012 11:37:30 +0100

Australia is considering steps to stop chemicals used in drug manufacturing from being diverted by terrorists to make explosives.

Tamil Nadu will be next manufacturing hit if makers meet WHO standards, says IDMA

Natalie.MORRISON@wrbm.com (Natalie MORRISON) — Mon, 06 Feb 2012 10:39:50 +0100

The Indian Drug Manufacturers Association (IDMA) plans to amp up pharma business in Tamil Nadu by helping more companies meet WHO production standards.

Anti addiction API helps Johnson Matthey grow in Q3

Gareth.MACDONALD@wrbm.com (Gareth MACDONALD) — Mon, 06 Feb 2012 13:05:17 +0100

Johnson Matthey says sales of an anti-addiction API were the key to gains made by its fine chemicals business in Q3.

People on the move: jobs in pharma

Natalie.MORRISON@wrbm.com (Natalie MORRISON) — Mon, 06 Feb 2012 12:53:24 +0100

in-PharmaTechnologist presents its round-up of the latest appointments in the pharmaceutical industry, including news from Prosonix, Savient and Dendreon.

US act aims to end shortages by speeding post-approval changes

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Mon, 06 Feb 2012 12:44:27 +0100

A US drug shortages act aims to make drug production more efficient by quickening review of post-approval manufacturing changes.

Annual WHO meeting to tackle spread of substandard drugs

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Mon, 06 Feb 2012 11:16:53 +0100

The WHO is urging countries to collaborate on tackling substandard drugs and strengthening supply chains at a new annual meeting.

CMO news roundup – Foster, Excella, Catalent and RohnerChem

Gareth.MACDONALD@wrbm.com (Gareth MACDONALD) — Thu, 02 Feb 2012 11:26:45 +0100

A round-up of news in the contract manufacturing space, with developments at Foster Delivery Sciences, Excella, Catalent and RohnerChem.

AstraZeneca to cut 1,350 ‘operations support’ jobs

Gareth.MACDONALD@wrbm.com (Gareth MACDONALD) — Thu, 02 Feb 2012 13:11:32 +0100

AstraZeneca will cut 1,350 operations jobs in the next few years as part of wide ranging restructuring move.

EU plan to add APIs to pollutant watch list could raise costs

Nick.TAYLOR@wrbm.com (Nick TAYLOR) — Thu, 02 Feb 2012 11:52:24 +0100

European Commission plans to add three APIs to its list of water polluting chemicals could result in costs to pharmaceutical companies.